Zum Hauptinhalt springen

Hepatitiden

03. März 2017 | Hepatitiden

Europe. Taking stock: where does Europe stand in the elimination of hepatitis B and C?

In 2016, a regional action plan for Europe that aims to contribute to the implementation of the global viral hepatitis elimination strategy was developed by the WHO Regional Office for Europe. In an article published today in Eurosurveillance, the a…

21. Februar 2017 | Hepatitiden

Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis.

Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. Chen G, Wang C, Chen J, Ji D, Wang Y, Wu V, Karlberg J, Lau G. Hepatology. 2017 Feb 13. doi: 10.1002/hep.29109…

21. Februar 2017 | Hepatitiden

Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study.

Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study. Zeng QL, Xu GH, Zhang JY, Li W, Zhang DW, Li ZQ, Liang HX, Li CX, Yu ZJ. J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30060-0. doi: 10.1016/j.jhep.2…

21. Februar 2017 | Hepatitiden

Real-world treatment for chronic hepatitis C infection in Germany. Analyses from drug prescription data, 2010 - 2015.

Real-world treatment for chronic hepatitis C infection in Germany. Analyses from drug prescription data, 2010 - 2015. Zimmermann R, Kollan C, Ingiliz P, Mauss S, Schmidt D, Bremer V. J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30059-4. doi: 10.1016/…

21. Februar 2017 | Hepatitiden

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. van der Ree MH, de Vree JM, Stelma F, Willemse S, van der Valk M, Rietdijk S, Molenkamp R, Schinkel J…

14. Februar 2017 | Hepatitiden

Hunderte Fälle von Leberversagen unter Therapie mit neuen Hepatitis-C-Medikamenten – Folge zu unselektiver Anwendung?

(...) Prof. Dr. Christoph Sarrazin: „Wir mussten schmerzhaft lernen, dass es einen Point of no Return gibt. Ab diesem Zeitpunkt in der Erkrankung kann man zwar mit den DAA das Virus aus dem Körper eliminieren, aber es gelingt nicht mehr…

12. Februar 2017 | Hepatitiden

INHSU - The International Network on Hepatitis in Substance Users

The International Network on Hepatitis in Substance Users (INHSU) is an international organization dedicated to scientific knowledge exchange, knowledge translation, and advocacy focused on hepatitis C prevention and care among people who use drugs…

Weitere
akutelle Informationen
zu den Themengebieten